Please ensure Javascript is enabled for purposes of website accessibility

Why BioCryst Pharmaceuticals Stock Is Soaring Today

By Keith Speights - May 6, 2021 at 11:06AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The drugmaker reported better-than-expected Q1 results.

What happened

Shares of BioCryst Pharmaceuticals (BCRX 1.88%) were soaring 14.5% higher as of 10:51 a.m. EDT on Thursday. The big gain came after the drugmaker provided its first-quarter update before the market opened.

So what

BioCryst had plenty of good news to share in its quarterly update. The company reported total revenue in Q1 of $19.1 million, more than doubling the consensus Wall Street revenue estimate of $8.9 million.

Gold dollar signs of increasingly larger size

Image source: Getty Images.

The primary driver of this strong growth was Orladeyo. The hereditary angioedema (HAE) drug generated net sales of $10.9 million in Q1, its first full quarter on the U.S. market. BioCryst stated that the majority of these sales came from new patients who switched to Orladeyo from other medications or from acute-only treatment.

In addition to its better-than-expected sales, BioCryst also announced that it's reached an agreement with the U.S. Food and Drug Administration (FDA) to use change from baseline in hemoglobin as the primary endpoint for its planned pivotal clinical studies evaluating BCX9930 in treating rare disease paroxysmal nocturnal hemoglobinuria (PNH). The company reported clinical results in March that showed the experimental drug achieved significant increases of hemoglobin in PNH patients.

Now what

The biotech stock could have several potential catalysts on the way. BioCryst received European Commission approval for Orladeyo on April 30. The company plans a commercial launch of the drug in Germany this quarter and will follow up by launching Orladeyo in other European markets. It also hopes to win U.K. approval of the drug.

Keith Speights has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

BioCryst Pharmaceuticals, Inc. Stock Quote
BioCryst Pharmaceuticals, Inc.
$14.64 (1.88%) $0.27

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/13/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.